98%
921
2 minutes
20
Mutations in the gene encoding the methyl-CG binding protein MeCP2 cause several neurological disorders including Rett syndrome. The di-nucleotide methyl-CG (mCG) is the classical MeCP2 DNA recognition sequence, but additional methylated sequence targets have been reported. Here we show by in vitro and in vivo analyses that MeCP2 binding to non-CG methylated sites in brain is largely confined to the tri-nucleotide sequence mCAC. MeCP2 binding to chromosomal DNA in mouse brain is proportional to mCAC + mCG density and unexpectedly defines large genomic domains within which transcription is sensitive to MeCP2 occupancy. Our results suggest that MeCP2 integrates patterns of mCAC and mCG in the brain to restrain transcription of genes critical for neuronal function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446194 | PMC |
http://dx.doi.org/10.1371/journal.pgen.1006793 | DOI Listing |
Orphanet J Rare Dis
September 2025
Unit of Child Neuropsychiatry, IRCCS Istituto Giannina Gaslini, Epicare Network for Rare Disease, Genoa, Italy.
Background: Rett Syndrome (RTT) is a rare, and severe neurodevelopmental disorder that primarily affects females and is primarily (> 96%) due to pathogenic loss-of-function genetic variants of methyl-CpG-binding protein 2 (MECP2). Despite the rarity of the syndrome, sporadic twin cases have been reported. The descriptions have often focused on the phenotype, emphasizing differences or similarities.
View Article and Find Full Text PDFiScience
September 2025
Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.
Recent discoveries showed that some chromatin-binding proteins also interact with RNA to regulate gene expression. Poly (ADP-ribose) polymerase 1 (PARP1) and methyl-CpG binding protein 2 (MeCP2) are two chromatin-associated, DNA-binding proteins that play central roles in gene expression, DNA damage response, and epigenetic regulation. Both proteins possess RNA-binding properties, but the mechanism by which PARP1 and MeCP2 recognize RNA-binding sites remains unclear.
View Article and Find Full Text PDFCells
August 2025
Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, 745 Bannatyne Avenue, Basic Medical Sciences Bldg. Room 627, Winnipeg, MB R3E 0J9, Canada.
Methyl CpG-binding protein 2 (MeCP2) is an epigenetic reader of DNA methylation with high abundance in the brain. While genetic mutations occur across different protein domains of MeCP2, the T158M mutation is amongst the most frequent MeCP2 mutations. MeCP2 is encoded by the / gene located on the X chromosome.
View Article and Find Full Text PDFPediatr Neurol
August 2025
Department of Neuropediatrics, Jena University Hospital, Jena, Germany; Center for Rare Diseases, Jena University Hospital, Jena, Germany. Electronic address:
Background: Rett syndrome, a neurodevelopmental disorder predominantly affecting females, is caused by variants in MECP2. Individuals experience a decline in skills, particularly involving language and hand function; nevertheless, studies of brain pathology suggest that neurodegeneration is not involved. To further investigate the presence of neurodegeneration, we measured serum neurofilament light chain (sNfL), a sensitive biomarker of neuronal damage.
View Article and Find Full Text PDFMol Cell Endocrinol
August 2025
Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Preeclampsia (PE) is a major pregnancy complication characterized by an aberrant immune response. Methyl CpG binding protein 2 (MeCP2) is a potential regulator of secreted frizzled-related protein 4 (SFRP4), and both MeCP2 and SFRP4 are implicated in immune homeostasis. This study investigated the regulatory role of MeCP2/SFRP4 in immune cells in PE.
View Article and Find Full Text PDF